Recently, we evaluated the performance of 190 candidate protein biomarkers to discriminate between patients with benign or malignant lung nodules. The candidate markers came from the substantial literature on cancer-associated proteins as well as from mass spectrometry studies, conducted in-house to identify proteins up-regulated either on the surface of tumors or in the secretome of tumors, as compared to adjacent normal lung tissue. Plasma samples were obtained retrospectively for analysis from those with either benign or malignant nodules. A 13 protein panel was identified with a high negative predictive value, able to remove approximately half of those with benign nodules from further consideration. The test has been commercialized, using MRM mass spectrometry, by Integrated Diagnostics.
Creating a Clinical Diagnostic Test from Discovery Through Launch with Mass Spectrometry
Video Apr 14, 2015
Recommended Videos
Video
In part one of "Microfluidics Adventures," brought to you by the Lutetium Project, Marie Boulez sets the scene and explains why it is so compelling to make products smaller, from a theoretical point of view. This first part of the three-part series will help you understand the physics concepts that are fundamental to microfluidics.
WATCH NOWLike what you just watched? You can find similar content on the communities below.
Analysis & Separations Diagnostics Proteomics & MetabolomicsTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
